Clinical Trials Logo

Corpus Callosum Malformation clinical trials

View clinical trials related to Corpus Callosum Malformation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03680651 Recruiting - Prenatal Disorder Clinical Trials

Frequency and Type of Genetic Abnormalities Found in Antenatal Corpus Callosum Malformation

AGMCC1318
Start date: June 18, 2018
Phase:
Study type: Observational

Corpus callosum malformation (CCM) is the most frequently detected cerebral defect diagnosed in the prenatal setting. The most common CCM is corpus callosum agenesis (CCA) which is found in 2 to 3% of patients presenting with intellectual disability. When CCM is diagnosed, the risk of chromosomal disorder is estimated to be 16%, be it aneuploidy such as trisomy 18, trisomy 13 or mosaic trisomy 8, or a chromosome structure anomaly, copy number variation or more complex rearrangement In France, since 2013 oligoarray-based comparative genomic hybridization (aCGH) analysis is performed in the prenatal period for most malformations after approval by a multidisciplinary prenatal diagnosis ethics committee (Centre Pluridisciplinaire de Diagnostic Prénatal, CPDPN) . However, to date only a few studies have been published which report recurrent Copy Number Variations (CNV) associated with CCM and estimate the risk for a chromosomal disorder, thus making counseling difficult in this context of prenatal diagnosis.

NCT ID: NCT03463239 Not yet recruiting - Urologic Diseases Clinical Trials

Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora

Start date: January 2025
Phase: Phase 1
Study type: Interventional

The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. Autologous endothelial and smooth muscle cells obtained from enrolled subjects' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa/albuginea constructs for repair of damaged penile tissues.